Pia Giovannelli, Marzia Di Donato, Fabrizio Licitra, Emilia Sabbatino, Viviana Tutino, Gabriella Castoria, Antimo Migliaccio
{"title":"Filamin A in triple negative breast cancer","authors":"Pia Giovannelli, Marzia Di Donato, Fabrizio Licitra, Emilia Sabbatino, Viviana Tutino, Gabriella Castoria, Antimo Migliaccio","doi":"10.1016/j.steroids.2024.109380","DOIUrl":null,"url":null,"abstract":"<div><p>Triple-negative breast cancer is a rare but highly heterogeneous breast cancer subtype with a limited choice of specific treatments. Chemotherapy remains the only efficient treatment, but its side effects and the development of resistance consolidate the urgent need to discover new targets. In TNBC, filamin A expression correlates to grade and TNM stage. Accordingly, this protein could constitute a new target for this BC subtype. Even if most of the data indicates its direct involvement in cancer progression, some contrasting results underline the need to deepen the studies. To elucidate a possible function of this protein as a TNBC marker, we summarized the main characteristic of filamin A and its involvement in physiological and pathological processes such as cancer. Lastly, we scrutinized its actions in triple-negative breast cancer and highlighted the need to increase the number of studies useful to better clarify the role of this versatile protein as a marker and target in TNBC, alone or in “collaboration” with other proteins with a relevant role in this BC subgroup.</p></div>","PeriodicalId":21997,"journal":{"name":"Steroids","volume":"205 ","pages":"Article 109380"},"PeriodicalIF":2.1000,"publicationDate":"2024-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.sciencedirect.com/science/article/pii/S0039128X24000187/pdfft?md5=6097b8c143a580ec072c1ebbb0512ded&pid=1-s2.0-S0039128X24000187-main.pdf","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Steroids","FirstCategoryId":"3","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S0039128X24000187","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Triple-negative breast cancer is a rare but highly heterogeneous breast cancer subtype with a limited choice of specific treatments. Chemotherapy remains the only efficient treatment, but its side effects and the development of resistance consolidate the urgent need to discover new targets. In TNBC, filamin A expression correlates to grade and TNM stage. Accordingly, this protein could constitute a new target for this BC subtype. Even if most of the data indicates its direct involvement in cancer progression, some contrasting results underline the need to deepen the studies. To elucidate a possible function of this protein as a TNBC marker, we summarized the main characteristic of filamin A and its involvement in physiological and pathological processes such as cancer. Lastly, we scrutinized its actions in triple-negative breast cancer and highlighted the need to increase the number of studies useful to better clarify the role of this versatile protein as a marker and target in TNBC, alone or in “collaboration” with other proteins with a relevant role in this BC subgroup.
三阴性乳腺癌是一种罕见但高度异质性的乳腺癌亚型,可供选择的特异性治疗方法有限。化疗仍然是唯一有效的治疗方法,但化疗的副作用和耐药性的产生使得发现新靶点的需求更加迫切。在 TNBC 中,丝胶蛋白 A 的表达与分级和 TNM 分期相关。因此,该蛋白可能成为这一BC亚型的新靶点。尽管大多数数据表明,丝胶蛋白 A 直接参与了癌症的进展,但一些截然不同的结果也凸显了深化研究的必要性。为了阐明该蛋白作为 TNBC 标志物的可能功能,我们总结了丝胺 A 的主要特征及其在癌症等生理和病理过程中的参与。最后,我们仔细研究了丝胶蛋白 A 在三阴性乳腺癌中的作用,并强调需要增加有用的研究数量,以更好地阐明这种多功能蛋白作为 TNBC 标志物和靶点的作用,无论是单独作用还是与其他蛋白 "合作 "作用。
期刊介绍:
STEROIDS is an international research journal devoted to studies on all chemical and biological aspects of steroidal moieties. The journal focuses on both experimental and theoretical studies on the biology, chemistry, biosynthesis, metabolism, molecular biology, physiology and pharmacology of steroids and other molecules that target or regulate steroid receptors. Manuscripts presenting clinical research related to steroids, steroid drug development, comparative endocrinology of steroid hormones, investigations on the mechanism of steroid action and steroid chemistry are all appropriate for submission for peer review. STEROIDS publishes both original research and timely reviews. For details concerning the preparation of manuscripts see Instructions to Authors, which is published in each issue of the journal.